Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
PRIMARY OBJECTIVE:
I. To explore the incidence of clinical complications associated with anti-VEGF-related therapies in cancer patients treated at Emory University and the University of Texas M.D. Anderson Cancer Center (MDACC).
SECONDARY OBJECTIVES:
I. To explore the correlation of clinical response rates to a novel blood pressure scoring system in cancer patients treated with anti-VEGF-related therapies.
II. To explore the correlation of objective response to each toxicity grade 3 or higher in cancer patients treated with anti-VEGF-related therapies.
III. To investigate the validity of a novel multi-parameter-based blood pressure scoring system and to determine if the new scoring method is concordant with the current Common Terminology Criteria for Adverse Events (CTCAE) method.
OUTLINE:
Patients' medical records are reviewed.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must be able to understand and be willing to sign a written informed consent document
Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy
Clareo Health | Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
